<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35117">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01868620</url>
  </required_header>
  <id_info>
    <org_study_id>13 030 03</org_study_id>
    <secondary_id>HAO</secondary_id>
    <nct_id>NCT01868620</nct_id>
  </id_info>
  <brief_title>Non-inferiority Trial of Iontophoretic Corneal Collagen Crosslinking (CXL) Compared to Standard Corneal Collagen Crosslinking in Progressive Keratoconus.</brief_title>
  <acronym>IONTO-CXL</acronym>
  <official_title>Non-inferiority Trial of Iontophoretic Corneal Collagen Crosslinking (CXL) Compared to Standard Corneal Collagen Crosslinking in Progressive Keratoconus.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sooft Italia</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre de Référence National du Kératocône (CRNK)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of the protocol is to compare the current standard CXL with
      iontophoretic CXL to provide evidence in relation to the efficacy and safety in progressive
      keratoconus.

      Corneal collagen crosslinking (CXL) is the first surgical procedure that appears to halt the
      progression of keratoconus. In the current standard CXL, the central corneal epithelium must
      be debrided to efficiently permeate the corneal stroma with riboflavin. The epithelium
      debridement can cause severe pain, infection and stromal haze. The study hypothesis is that
      iontophorese CXL is as effective as standard CXL to stabilize a progressive keratoconus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Keratoconus is a common bilateral progressive corneal ecstatic disease causing visual
      impairment by inducing irregular astigmatism and corneal opacities. This disorder typically
      begins during teenage years, progresses until the age of 30 to 40 years and, in severe
      forms, may need a corneal transplantation. CXL has changed the natural evolution of
      keratoconus. It creates links between collagen fibrils in order to rigidify the corneal
      stroma and slow down the progression of keratoconus. The corneal stroma is soaked with a
      riboflavin solution before being exposed to ultraviolet-A radiation.

      In the current standard CXL, the central corneal epithelium must be debrided to allow the
      penetration of riboflavin into the cornea with a risk of side effects, such as pain for the
      first two post-operative days, temporary loss of visual acuity during the first three
      months, and serious complications such as infection and stromal opacity due to corneal
      scarring.

      Iontophoresis is a non invasive technique in which a weak electric current is used to
      enhance the penetration of riboflavin into the cornea. The iontophoresis technique could
      allow intrastromal riboflavin diffusion, while keeping the corneal epithelium on, combining
      the efficiency of the standard procedure without the side effects of epithelial debridement.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The main outcome parameter is the non-inferiority of iontophoretic CXL compared to standard CXL in progressive keratoconus</measure>
    <time_frame>Outcome measure is assessed at 1 year.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measuring maximum keratometry (K-max) derived from computerized videokeratography.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of minimum keratometry</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measure assessed by tomographic measurement.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Comparison of mean keratometry</measure>
    <time_frame>At 1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tomographic measurement.</description>
  </other_outcome>
  <other_outcome>
    <measure>Comparison of postoperative pain and complications during the follow up</measure>
    <time_frame>Outcome measure is assessed at 1 year and at 3 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Comparison of visual acuity</measure>
    <time_frame>Outcome measure is assessed at 1 year and at 3 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Intraoperative comparison of corneal concentration of riboflavin</measure>
    <time_frame>Outcome measure is assessed at 1 year and at 3 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Comparison of depth of treatment</measure>
    <time_frame>Outcome measure is assessed at 1 year and at 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>By tomographic measurement</description>
  </other_outcome>
  <other_outcome>
    <measure>Comparison of biomechanical parameters</measure>
    <time_frame>Outcome measure is assessed at 1 year and at 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>By ORA (Ocular Response Analyzer)</description>
  </other_outcome>
  <other_outcome>
    <measure>Comparison of corneal thickness</measure>
    <time_frame>Outcome measure is assessed at 1 year and at 3 months for the tomographic measurement.</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">162</enrollment>
  <condition>Progressive Keratoconus</condition>
  <arm_group>
    <arm_group_label>Iontophoretic CXL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The iontophoretic CXL involves a constant current source and two electrodes. The main electrode is a circular cup, with a surrounding annular suction ring to affix the device on the cornea during the procedure. The electrode itself is a stainless steel grid, placed into the cup at a minimal distance from the cornea. The reservoir is filled with riboflavin solution. The generator applies a constant current of 1mA for a preset period of 5 min. After the riboflavin administration by iontophoresis, the cornea is irradiated by a UVA light for 3mW/cm2 during 30 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard CXL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In the standard CXL, the epithelium is mechanically removed. Then, a solution of riboflavin is instilled each minute for 30 minutes. Corneas are irradiated by a UVA light for 3mW/cm2 during 30 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Iontophoretic CXL</intervention_name>
    <arm_group_label>Iontophoretic CXL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard CXL</intervention_name>
    <arm_group_label>Standard CXL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years old

          -  Corneal thickness ≥ 400 µm

          -  Progressive stage 1 to 3 keratoconus (Krumeich classification)

        Exclusion Criteria:

          -  Corneal thickness &lt; 400µm

          -  Stage 4 keratoconus (Krumeich classification)

          -  Concomitant corneal disease

          -  History of corneal surgery
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François MALECAZE, MD, PhD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_contact>
    <last_name>François MALECAZE, MD, PhD</last_name>
    <phone>0561777752</phone>
    <phone_ext>33</phone_ext>
    <email>malecaze.fr@chu-toulouse.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Toulouse</name>
      <address>
        <city>Toulouse</city>
        <state>Midi-Pyrenees</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François MALECAZE, MD, PhD</last_name>
      <phone>0561777752</phone>
      <phone_ext>33</phone_ext>
      <email>malecaze.fr@chu-toulouse.fr</email>
    </contact>
    <contact_backup>
      <last_name>Pierre FOURNIE, MD, PhD</last_name>
      <phone>0561777404</phone>
      <phone_ext>33</phone_ext>
      <email>fournie.p@chu-toulouse.fr</email>
    </contact_backup>
    <investigator>
      <last_name>François MALECAZE, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre FOURNIE, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Krachmer JH, Feder RS, Belin MW. Keratoconus and related noninflammatory corneal thinning disorders. Surv Ophthalmol. 1984 Jan-Feb;28(4):293-322. Review.</citation>
    <PMID>6230745</PMID>
  </reference>
  <reference>
    <citation>Kennedy RH, Bourne WM, Dyer JA. A 48-year clinical and epidemiologic study of keratoconus. Am J Ophthalmol. 1986 Mar 15;101(3):267-73.</citation>
    <PMID>3513592</PMID>
  </reference>
  <reference>
    <citation>Rabinowitz YS. Keratoconus. Surv Ophthalmol 1998;42:297-319</citation>
  </reference>
  <reference>
    <citation>Zadnik K, Barr JT, Gordon MO, Edrington TB. Biomicroscopic signs and disease severity in keratoconus. Collaborative Longitudinal Evaluation of Keratoconus (CLEK) Study Group. Cornea. 1996 Mar;15(2):139-46. Review.</citation>
    <PMID>8925661</PMID>
  </reference>
  <reference>
    <citation>McMahon TT, Edrington TB, Szczotka-Flynn L, Olafsson HE, Davis LJ, Schechtman KB; CLEK Study Group. Longitudinal changes in corneal curvature in keratoconus. Cornea. 2006 Apr;25(3):296-305.</citation>
    <PMID>16633030</PMID>
  </reference>
  <reference>
    <citation>Zadnik K, Steger-May K, Fink BA, Joslin CE, Nichols JJ, Rosenstiel CE, Tyler JA, Yu JA, Raasch TW, Schechtman KB; CLEK Study Group. Collaborative Longitudinal Evaluation of Keratoconus. Between-eye asymmetry in keratoconus. Cornea. 2002 Oct;21(7):671-9.</citation>
    <PMID>12352084</PMID>
  </reference>
  <reference>
    <citation>Rabinowitz YS, Nesburn AB, McDonnell PJ. Videokeratography of the fellow eye in unilateral keratoconus. Ophthalmology. 1993 Feb;100(2):181-6.</citation>
    <PMID>8437824</PMID>
  </reference>
  <reference>
    <citation>Krumeich JH, Daniel J, Knülle A. Live-epikeratophakia for keratoconus. J Cataract Refract Surg. 1998 Apr;24(4):456-63.</citation>
    <PMID>9584238</PMID>
  </reference>
  <reference>
    <citation>Colin J, Malet FJ. Intacs for the correction of keratoconus: two-year follow-up. J Cataract Refract Surg. 2007 Jan;33(1):69-74.</citation>
    <PMID>17189796</PMID>
  </reference>
  <reference>
    <citation>Ertan A, Kamburoğlu G. Intacs implantation using a femtosecond laser for management of keratoconus: Comparison of 306 cases in different stages. J Cataract Refract Surg. 2008 Sep;34(9):1521-6. doi: 10.1016/j.jcrs.2008.05.028.</citation>
    <PMID>18721713</PMID>
  </reference>
  <reference>
    <citation>Cheng YY, Visser N, Schouten JS, Wijdh RJ, Pels E, van Cleynenbreugel H, et al. Endothelial cell loss and visual outcome of deep anterior lamellar keratoplasty versus penetrating keratoplasty: a randomized multicenter clinical trial. Ophthalmology 2011;118:302-9.</citation>
  </reference>
  <reference>
    <citation>Epstein RJ, Seedor JA, Dreizen NG, Stulting RD, Waring GO 3rd, Wilson LA, Cavanagh HD. Penetrating keratoplasty for herpes simplex keratitis and keratoconus. Allograft rejection and survival. Ophthalmology. 1987 Aug;94(8):935-44.</citation>
    <PMID>3309775</PMID>
  </reference>
  <reference>
    <citation>Kirkness CM, Ficker LA, Steele AD, Rice NS. The success of penetrating keratoplasty for keratoconus. Eye (Lond). 1990;4 ( Pt 5):673-88.</citation>
    <PMID>2282941</PMID>
  </reference>
  <reference>
    <citation>The Australian Corneal Graft Registry. 1990 to 1992 report. Aust N Z J Ophthalmol. 1993 May;21(2 Suppl):1-48. Review.</citation>
    <PMID>8333942</PMID>
  </reference>
  <reference>
    <citation>Borderie VM, Boëlle PY, Touzeau O, Allouch C, Boutboul S, Laroche L. Predicted long-term outcome of corneal transplantation. Ophthalmology. 2009 Dec;116(12):2354-60. doi: 10.1016/j.ophtha.2009.05.009. Epub 2009 Oct 7.</citation>
    <PMID>19815285</PMID>
  </reference>
  <reference>
    <citation>Spoerl E, Huhle M, Seiler T. Induction of cross-links in corneal tissue. Exp Eye Res. 1998 Jan;66(1):97-103.</citation>
    <PMID>9533835</PMID>
  </reference>
  <reference>
    <citation>Wollensak G, Spoerl E, Seiler T. Stress-strain measurements of human and porcine corneas after riboflavin-ultraviolet-A-induced cross-linking. J Cataract Refract Surg. 2003 Sep;29(9):1780-5.</citation>
    <PMID>14522301</PMID>
  </reference>
  <reference>
    <citation>Raiskup-Wolf F, Hoyer A, Spoerl E, Pillunat LE. Collagen crosslinking with riboflavin and ultraviolet-A light in keratoconus: long-term results. J Cataract Refract Surg. 2008 May;34(5):796-801.</citation>
    <PMID>18471635</PMID>
  </reference>
  <reference>
    <citation>Wittig-Silva C, Whiting M, Lamoureux E, Lindsay RG, Sullivan LJ, Snibson GR. A randomized controlled trial of corneal collagen cross-linking in progressive keratoconus: preliminary results. J Refract Surg. 2008 Sep;24(7):S720-5.</citation>
    <PMID>18811118</PMID>
  </reference>
  <reference>
    <citation>Koller T, Mrochen M, Seiler T. Complication and failure rates after corneal crosslinking. J Cataract Refract Surg. 2009 Aug;35(8):1358-62. doi: 10.1016/j.jcrs.2009.03.035.</citation>
    <PMID>19631120</PMID>
  </reference>
  <reference>
    <citation>Wollensak G, Spoerl E, Seiler T. Riboflavin/ultraviolet-a-induced collagen crosslinking for the treatment of keratoconus. Am J Ophthalmol. 2003 May;135(5):620-7.</citation>
    <PMID>12719068</PMID>
  </reference>
  <reference>
    <citation>Caporossi A, Baiocchi S, Mazzotta C, Traversi C, Caporossi T. Parasurgical therapy for keratoconus by riboflavin-ultraviolet type A rays induced cross-linking of corneal collagen: preliminary refractive results in an Italian study. J Cataract Refract Surg. 2006 May;32(5):837-45.</citation>
    <PMID>16765803</PMID>
  </reference>
  <reference>
    <citation>Mazzotta C, Balestrazzi A, Baiocchi S, Traversi C, Caporossi A. Stromal haze after combined riboflavin-UVA corneal collagen cross-linking in keratoconus: in vivo confocal microscopic evaluation. Clin Experiment Ophthalmol. 2007 Aug;35(6):580-2.</citation>
    <PMID>17760642</PMID>
  </reference>
  <reference>
    <citation>Pollhammer M, Cursiefen C. Bacterial keratitis early after corneal crosslinking with riboflavin and ultraviolet-A. J Cataract Refract Surg. 2009 Mar;35(3):588-9. doi: 10.1016/j.jcrs.2008.09.029.</citation>
    <PMID>19251154</PMID>
  </reference>
  <reference>
    <citation>Rama P, Di Matteo F, Matuska S, Paganoni G, Spinelli A. Acanthamoeba keratitis with perforation after corneal crosslinking and bandage contact lens use. J Cataract Refract Surg. 2009 Apr;35(4):788-91. doi: 10.1016/j.jcrs.2008.09.035.</citation>
    <PMID>19304108</PMID>
  </reference>
  <reference>
    <citation>Kymionis GD, Portaliou DM, Bouzoukis DI, Suh LH, Pallikaris AI, Markomanolakis M, Yoo SH. Herpetic keratitis with iritis after corneal crosslinking with riboflavin and ultraviolet A for keratoconus. J Cataract Refract Surg. 2007 Nov;33(11):1982-4.</citation>
    <PMID>17964410</PMID>
  </reference>
  <reference>
    <citation>Kymionis GD, Portaliou DM, Pallikaris IG. Additional complications of corneal crosslinking. J Cataract Refract Surg. 2010 Jan;36(1):185; author reply 186. doi: 10.1016/j.jcrs.2009.07.028.</citation>
    <PMID>20117734</PMID>
  </reference>
  <reference>
    <citation>Baiocchi S, Mazzotta C, Cerretani D, Caporossi T, Caporossi A. Corneal crosslinking: riboflavin concentration in corneal stroma exposed with and without epithelium. J Cataract Refract Surg. 2009 May;35(5):893-9. doi: 10.1016/j.jcrs.2009.01.009.</citation>
    <PMID>19393890</PMID>
  </reference>
  <reference>
    <citation>Caporossi A, Mazzotta C, Baiocchi S, Cporossi T, Paradiso AL. Transepithelial corneal collagen crosslinking for keratoconus: qualitative investigation by in vivo HRT II confocal analysis. Eur J Ophthalmol 2012;22:81-8.</citation>
  </reference>
  <reference>
    <citation>Boxer Wachler BS, Pinelli R, Ertan A, Chan CC. Safety and efficacy of transepithelial crosslinking (C3-R/CXL). J Cataract Refract Surg. 2010 Jan;36(1):186-8; author reply 188-9. doi: 10.1016/j.jcrs.2009.08.019.</citation>
    <PMID>20117737</PMID>
  </reference>
  <reference>
    <citation>Filipello M, Stagni E, O'Brart D. Transepithelial corneal collagen crosslinking: bilateral study. J Cataract Refract Surg 2012;38:283-91.</citation>
  </reference>
  <reference>
    <citation>Filippello M, Stagni E, O'Brart D. Reply: Efficacy and safety of transepithelial corneal collagen crosslinking. J Cataract Refract Surg 2012;38:1304-5.</citation>
  </reference>
  <reference>
    <citation>Costello CT, Jeske AH. Iontophoresis: applications in transdermal medication delivery. Phys Ther. 1995 Jun;75(6):554-63. Review.</citation>
    <PMID>7770500</PMID>
  </reference>
  <reference>
    <citation>Jones RF, Maurice DM. New methods of measuring the rate of aqueous flow in man with fluorescein. Exp Eye Res. 1966 Jul;5(3):208-20.</citation>
    <PMID>5914653</PMID>
  </reference>
  <reference>
    <citation>Hughes L, Maurice DM. A fresh look at iontophoresis. Arch Ophthalmol. 1984 Dec;102(12):1825-9.</citation>
    <PMID>6508622</PMID>
  </reference>
  <reference>
    <citation>Lam TT, Edward DP, Zhu XA, Tso MO. Transscleral iontophoresis of dexamethasone. Arch Ophthalmol. 1989 Sep;107(9):1368-71.</citation>
    <PMID>2783069</PMID>
  </reference>
  <reference>
    <citation>Behar-Cohen FF, Parel JM, Pouliquen Y, Thillaye-Goldenberg B, Goureau O, Heydolph S, Courtois Y, De Kozak Y. Iontophoresis of dexamethasone in the treatment of endotoxin-induced-uveitis in rats. Exp Eye Res. 1997 Oct;65(4):533-45.</citation>
    <PMID>9464186</PMID>
  </reference>
  <reference>
    <citation>Yoo SH, Dursun D, Dubovy S, Miller D, Alfonso E, Forster RK, Behar-Cohen F, Parel JM. Lontophoresis for the treatment of paecilomyces keratitis. Cornea. 2002 Jan;21(1):131-2.</citation>
    <PMID>11805526</PMID>
  </reference>
  <reference>
    <citation>Parkinson TM, Ferguson E, Febbraro S, Bakhtyari A, King M, Mundasad M. Tolerance of ocular iontophoresis in healthy volunteers. J Ocul Pharmacol Ther. 2003 Apr;19(2):145-51.</citation>
    <PMID>12804059</PMID>
  </reference>
  <reference>
    <citation>Horwath-Winter J, Schmut O, Haller-Schober EM, Gruber A, Rieger G. Iodide iontophoresis as a treatment for dry eye syndrome. Br J Ophthalmol. 2005 Jan;89(1):40-4.</citation>
    <PMID>15615744</PMID>
  </reference>
  <reference>
    <citation>Behar-Cohen FF, El Aouni A, Gautier S, David G, Davis J, Chapon P, Parel JM. Transscleral Coulomb-controlled iontophoresis of methylprednisolone into the rabbit eye: influence of duration of treatment, current intensity and drug concentration on ocular tissue and fluid levels. Exp Eye Res. 2002 Jan;74(1):51-9.</citation>
    <PMID>11878818</PMID>
  </reference>
  <reference>
    <citation>Eljarrat-Binstock E, Orucov F, Frucht-Pery J, Pe'er J, Domb AJ. Methylprednisolone delivery to the back of the eye using hydrogel iontophoresis. J Ocul Pharmacol Ther. 2008 Jun;24(3):344-50. doi: 10.1089/jop.2007.0097. PubMed PMID: 18476804.</citation>
    <PMID>18476804</PMID>
  </reference>
  <reference>
    <citation>Wollensak G, Spoerl E, Wilsch M, Seiler T. Endothelial cell damage after riboflavin-ultraviolet-A treatment in the rabbit. J Cataract Refract Surg. 2003 Sep;29(9):1786-90.</citation>
    <PMID>14522302</PMID>
  </reference>
  <reference>
    <citation>Spoerl E, Seiler T. Techniques for stiffening the cornea. J Refract Surg. 1999 Nov-Dec;15(6):711-3.</citation>
    <PMID>10590015</PMID>
  </reference>
  <reference>
    <citation>Chien YW, Banga AK. Iontophoretic (transdermal) delivery of drugs: overview of historical development. J Pharm Sci. 1989 May;78(5):353-4. Review.</citation>
    <PMID>2664122</PMID>
  </reference>
  <reference>
    <citation>Reinhart WJ, Musch DC, Jacobs DS, Lee WB, Kaufman SC, Shtein RM. Deep anterior lamellar keratoplasty as an alternative to penetrating keratoplasty: a report by the American academy of ophthalmology. Ophthalmology 2011;118:209-18.</citation>
  </reference>
  <reference>
    <citation>Caporossi A, Mazzotta C, Baiocchi S, Caporossi T. Long-term results of riboflavin ultraviolet a corneal collagen cross-linking for keratoconus in Italy: the Siena eye cross study. Am J Ophthalmol 2010;149:585-93. Epub 2010 Feb 6.</citation>
  </reference>
  <reference>
    <citation>Asri D, Touboul D, Fournié P, Malet F, Garra C, Gallois A, et al. Corneal collagen crosslinking in progressive keratoconus: multicenter results from the French National Center for Keratoconus. J Cataract Refract Surg 2011;37:2137-43.</citation>
  </reference>
  <reference>
    <citation>Vimalin J, Gupta N, Jambulingam M, Padmanabhan P, Madhavan HN. The effect of riboflavin-UV-A treatment on corneal limbal epithelial cells. A study on human cadaver eyes. Cornea 2012 Jun 5.</citation>
  </reference>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 25, 2013</lastchanged_date>
  <firstreceived_date>May 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Progressive keratoconus</keyword>
  <keyword>standard CXL</keyword>
  <keyword>iontophoretic CXL</keyword>
  <keyword>keratometry</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Keratoconus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
